邻苯二甲酸氢钠 | 827-27-0

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 邻苯二甲酸氢钠
• 中文别名: 邻苯二甲酸钠盐；苯二甲酸氢钠
• 英文名称: Phthalic Acid Disodium Salt
• CAS: 827-27-0；15968-01-1；10197-71-4
• 化学式: C8H6NaO4
• 分子量: 189.12
• InChiKey: DFLCZDIXTAAMLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P271,P304+P340,P312,P403+P233,P405,P501
• 危险性描述：
  H335

制备方法与用途

用途：在中和法中作为基准，配制缓冲溶液，以及用于有机合成。

文献信息

• Water soluble prodrugs of COX-2 inhibitors
  申请人：Payne E. Joseph

  公开号：US20060189682A1

  公开（公告）日：2006-08-24

  Disclosed are water soluble compounds which are useful as prodrugs of COX-2 inhibitors, and pharmaceutical compositions comprising them.

  揭示了作为COX-2抑制剂的前药有用的水溶性化合物，以及包含它们的药物组合物。
• [EN] PRODRUGS OF MYELOPEROXIDASE INHIBITORS<br/>[FR] PROMÉDICAMENTS D'INHIBITEURS DE LA MYÉLOPEROXYDASE
  申请人：BIOHAVEN THERAPEUTICS LTD

  公开号：WO2021072140A1

  公开（公告）日：2021-04-15

  Disclosed are prodrugs of myeloperoxidase (MPO) inhibitors, methods of treating MPO related disorders, e.g., multiple system atrophy, amyotrophic lateral sclerosis, and Huntingtons disease, and methods of neuroprotection, which include administering to a patient in need thereof the prodrugs, pharmaceutical compositions including the prodrugs, and kits including the pharmaceutical compositions and instructions for use.

  揭示了髓过氧化物酶（MPO）抑制剂的前药，治疗MPO相关疾病的方法，例如多系统萎缩症、肌萎缩侧索硬化和亨廷顿病，以及神经保护方法，包括向需要的患者施用前药，包括前药的药物组合物，以及包括药物组合物和使用说明的工具包。
• [EN] POLYETHYLENE GLYCOL CONJUGATES OF HETEROCYCLOALKYL CARBOXAMIDO PROPANOIC ACIDS<br/>[FR] CONJUGUES A BASE DE POLYETHYLENE GLYCOL D'ACIDES HETEROCYCLOALKYL CARBOXAMIDO PROPANOIQUES
  申请人：ELAN PHARM INC

  公开号：WO2005070921A1

  公开（公告）日：2005-08-04

  Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer’s disease, atherosclerosis, AIDS, dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

  公开的是结合VLA-4的偶联物。其中一些偶联物还抑制白细胞粘附，尤其是VLA-4介导的白细胞粘附。这类偶联物可用于治疗哺乳动物患者，如人类的炎症性疾病，例如哮喘、阿尔茨海默病、动脉粥样硬化、艾滋病、痴呆、糖尿病、炎症性肠病、类风湿性关节炎、组织移植、肿瘤转移和心肌缺血。这些偶联物还可用于治疗炎症性脑病，如多发性硬化症。
• Multimeric VLA-4 antagonists comprising polymer moieties
  申请人：Konradi W. Andrei

  公开号：US20060013799A1

  公开（公告）日：2006-01-19

  Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

  公开的是结合VLA-4的偶联物。其中一些偶联物还能抑制白细胞粘附，特别是VLA-4介导的白细胞粘附。这类偶联物可用于治疗哺乳动物患者，如人类的炎症性疾病，例如哮喘、阿尔茨海默病、动脉粥样硬化、艾滋病痴呆、糖尿病、炎症性肠病、类风湿性关节炎、组织移植、肿瘤转移和心肌缺血。这些偶联物还可用于治疗炎症性脑病，如多发性硬化症。
• Method of separating imide compound
  申请人：——

  公开号：US20020169331A1

  公开（公告）日：2002-11-14

  A reaction product and an imide compound can be separated from a reaction mixture obtained by reacting a substrate in the presence of the imide compound having an imide unit represented by the following formula (1): 1 wherein X represents an oxygen atom, a hydroxyl group or an acyloxy group by (A1) a solvent-crystallization step for crystallizing the imide compound with at least one solvent selected from the group consisting of a hydrocarbon, a chain ether and water, (A2) a cooling-crystallization step for crystallizing the reaction product by cooling, or (B) an extraction step for distributing the reaction product into a phase of a water-insoluble solvent and the imide compound into a phase of an aqueous solvent, respectively by using the aqueous solvent containing at least water and the water-insoluble solvent separable from the aqueous solvent. Further, the imide compound and the metal catalyst can be separated from a mixture containing the imide compound and the metal catalyst by (C) a solvent-crystallization step for crystallizing the imide compound by using a solvent for crystallization, (D) an absorption step for absorbing the metal catalyst by an absorption treatment, or (E) an extraction step for distributing the imide compound into a phase of a water-insoluble solvent and the metal catalyst into a phase of an aqueous solvent, respectively by using the aqueous solvent containing at least water and the water-insoluble solvent separable from the aqueous solvent.

  一种反应产物和一种亚酰亚胺化合物可以从通过在亚酰亚胺化合物存在的情况下将底物反应得到的反应混合物中分离出来，该亚酰亚胺化合物具有以下式（1）所表示的亚酰亚胺单元： 1 其中X代表氧原子、羟基或酰氧基 通过（A1）用羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和水等羟烃、链醚和